Evidence map›Paper›PMID 27454431›Full record

ArticlePloS one2016

Tubular Overexpression of Angiopoietin-1 Attenuates Renal Fibrosis.

Sudhir Singh, Scott R Manson, Heedoo Lee, Yeawon Kim, Tuoen Liu, Qiusha Guo, Julio J Geminiani, Paul F Austin, Ying Maggie Chen

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. JYYS Granule Mitigates Renal Injury in Clinic and in Spontaneously Hypertensive Rats by Inhibiting NF-Evidence-based complementary and alternative medicine : eCAM · 2018
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Sudhir SinghDivision of Nephrology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, United States of America.
Scott R MansonDivision of Urology, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States of America.
Heedoo LeeDivision of Nephrology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, United States of America.
Yeawon KimDivision of Nephrology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, United States of America.
Tuoen LiuOncology Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, United States of America.
Qiusha GuoDivision of Urology, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States of America.
Julio J GeminianiDivision of Urology, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States of America.
Paul F AustinDivision of Urology, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States of America.
Ying Maggie ChenDivision of Nephrology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, United States of America.
Washington University in St. Louis · US

Funding

Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
WU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI Jennifer Lynn Powers Carson · 2013 to 2026
$27.1M
Training Program in Clinical & Translationa Research in Human Glomerular DiseaseU54DK083912 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOLZMAN, LAWRENCE B. · 2009 to 2023
$20.3M
The Role of the Osteoblast Secretome in Bone FormationP30AR057235 · NIAMS · WASHINGTON UNIVERSITY · PI SILVA, MATTHEW J · 2009 to 2018
$5.7M
Washington University Center for Kidney Disease ResearchP30DK079333 · NIDDK · WASHINGTON UNIVERSITY · PI HAMMERMAN, MARC RANDALL · 2007 to 2011
$5.1M
THE ROLE OF BMP-7 IN THE PATHOGENESIS AND TREATMENT OF OBSTRUCTIVE UROPATHIESR01DK096177 · NIDDK · WASHINGTON UNIVERSITY · PI AUSTIN, PAUL F · 2012 to 2016
$1.6M
Mutant Laminin Chains and Nephrotic SyndromeK08DK089015 · NIDDK · WASHINGTON UNIVERSITY · PI CHEN, YING MAGGIE · 2010 to 2014
$641k
PHARMACOLOGICAL RESCUE OF MUTANT LAMININ IN NEPHROTIC SYNDROMER03DK106451 · NIDDK · WASHINGTON UNIVERSITY · PI CHEN, YING MAGGIE · 2015 to 2016
$153k
NCATS NIH HHS UL1 TR000448NIAMS NIH HHS P30 AR057235NIDDK NIH HHS K08 DK089015NIDDK NIH HHS P30 DK020579NIDDK NIH HHS P30 DK079333NIDDK NIH HHS R01 DK096177NIDDK NIH HHS R03 DK106451NIDDK NIH HHS U54 DK083912
6 · The paper itself

Abstract

Emerging evidence has highlighted the pivotal role of microvasculature injury in the development and progression of renal fibrosis. Angiopoietin-1 (Ang-1) is a secreted vascular growth factor that binds to the endothelial-specific Tie2 receptor. Ang-1/Tie2 signaling is critical for regulating blood vessel development and modulating vascular response after injury, but is dispensable in mature, quiescent vessels. Although dysregulation of vascular endothelial growth factor (VEGF) signaling has been well studied in renal pathologies, much less is known about the role of the Ang-1/Tie2 pathway in renal interstitial fibrosis. Previous studies have shown contradicting effects of overexpressing Ang-1 systemically on renal tubulointerstitial fibrosis when different engineered forms of Ang-1 are used. Here, we investigated the impact of site-directed expression of native Ang-1 on the renal fibrogenic process and peritubular capillary network by exploiting a conditional transgenic mouse system [Pax8-rtTA/(TetO)7 Ang-1] that allows increased tubular Ang-1 production in adult mice. Using a murine unilateral ureteral obstruction (UUO) fibrosis model, we demonstrate that targeted Ang-1 overexpression attenuates myofibroblast activation and interstitial collagen I accumulation, inhibits the upregulation of transforming growth factor β1 and subsequent phosphorylation of Smad 2/3, dampens renal inflammation, and stimulates the growth of peritubular capillaries in the obstructed kidney. Our results suggest that Ang-1 is a potential therapeutic agent for targeting microvasculature injury in renal fibrosis without compromising the physiologically normal vasculature in humans.

Indexed as

Gene ExpressionActinsAngiopoietin-1AnimalsBiomarkersCollagen Type IDisease Models, AnimalFibrosisGene Expression RegulationKidney DiseasesKidney TubulesMiceMice, TransgenicMicrocirculationNeovascularization, PathologicSignal TransductionActinsalpha-smooth muscle actin, mouseAngiopoietin-1BiomarkersCollagen Type ITransforming Growth Factor beta1

Identifiers

PMID27454431
PMCPMC4959721
OpenAlexW2499091050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.